Consequences of the implementation of "K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease" in a population of patients on chronic hemodialysis

Journal of Nephrology

Volumn 20, Issue 4, 2007, Pages 453-461

  Arenas, María Dolores ^a   Álvarez Ude, Fernando ^b   Torregrosa, Vicente ^c   Gil, María Teresa ^a   Carretón, María Antonia ^a   Moledous, Analía ^a   Nuñez, Carlos ^a   Devesa, Ramón ^a   Albiach, Begoña ^a  

^a Sanatorio Perpetuo Socorro   (Spain)

^b HOSPITAL GENERAL DE SEGOVIA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Bone metabolism; Calcium; K DOQI target; NKF K DOQI clinical practice guidelines; Phosphorus; PTH

Indexed keywords

ALFACALCIDOL; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM SALT; DIALYSIS FLUID; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER;

ADULT; AGED; ARTICLE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIALYSATE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PRESCRIPTION; RENAL OSTEODYSTROPHY; SIDE EFFECT;

AGED; BONE AND BONES; CALCIUM; CHELATING AGENTS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; POLYAMINES; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; RENAL OSTEODYSTROPHY; RETROSPECTIVE STUDIES; VITAMIN D;

EID: 36048947235     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. National Kidney Foundation. K/DOQI clinical practice guideline for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (Suppl 3): S1-201.
2. Arenas MD, Alvarez-Ude F, Gil MT, Soriano A, Egea JJ, Milian I, Amoedo ML, Muray S, Carreton MA. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units. Nephrol Dial Trasplant 2006; 21: 1663-8.
3. Medical expert group; Cannata-Andía JB, Coen G, Cunningham J, London G, Olgaard K. Clinical algorithms on renal osteodystrophy. Nephrol Dial Trasplant 2000; 15 (Suppl 5): 42-53.
4. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-87.
5. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-18.
6. Shahapuni I, Mansour J, Harbouche L, Maouad B, Benyahia M, Rahmouni K, Oprislu R, Bonne JF, Monge M, El Esper N, Presne C, Moriniere P, Choukroun G, Fournier A. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients? Semin Dial 2005; 18; 226-38.
7. Morige M, Shahapuni I, Oprisiu R, El Esper N, Moriniere P, Massy Z, Choukroun G, Fournier A. Reappraisal of 2003 NFK-K-DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients. Nat Clin Pract Nephrol 2006; 2: 326-36.
8. Naveh-Many T, Silver J. Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J Clin Invest 1990; 86: 1313-9.
9. Silver J, Kilav R, Naveh-Many T. Mechanisms of secondary hyperparathyroldism. Am J Physiol Renal Physiol 2002; 283: 367-76.
10. Tetta C, Gallieni M, Panichi V, Brancaccio D. Vascular calcifications as a footprint of increased calcium load and chronic inflammation in uremic patients: a need for a neutral calcium balance during hemodialysis? Int J Artif Organs 2002; 25: 18-26.
11. Coladonato JA. Control of hyperphosphatemia among patients with ESRD. J Am Soc Nephrol 2005; 16 (Suppl 2); S107-14.
12. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drueke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCI. Kidney Int 2005; 67: 760-71.
13. Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1311-4.
14. Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 2003; 64: 1653-61.
15. Goodman WG. Medical management of secondary hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant 2003; 18 (Suppl 3): iii2-8.
16. Albaaj F, Hutchison A. Hyperphosphataemia in renal failure: causes, consequences and current management. Drugs 2003; 63: 577-96.
17. Fiedler R, Deuber HJ, Langer T, Osten B, Mohan S, Jehle PM. Effects of reduced dialysate calcium on calcium-phosphorus product and bone metabolism in hemodialysis patients. Nephron Clin Pract 2004; 96: 3-9.
18. Rudnicki M, Frolich A, Haaber A, Tvedegaard E, Thode J, Serum ionized calcium, parathyroid hormone and phosphate in uremic patients during and between hemodialysis. Clin Nephrol 1993; 40: 225-9.
19. K/DOQ clinical practice guidelines for bone metabolism and disease in chronic in chronic kidney disease. With comments from: Cannata-Andia J, Coen G, Cuninghan J, London G, Olgaard K. Brussels, Belgium: OCC Europe, on behalf of Amgen (Europe) 2003.
20. Goodman WG, Belin T, Gales B, Juppner H, Segre GV, Salusky IB. Calcium-regulated parathyrold hormone release in patients with mild or advanced secondary hyperparathyroidism. Kidney Int 1995; 48: 1553-8.
21. Al Aly Z, Gonzalez EA, Martin KJ, Gellens ME. Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle. Am J Nephrol 2004; 24: 422-6.